Middleby Corp (MIDD) Misses Q4 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
Go back to Middleby Corp (MIDD) Misses Q4 EPS by 9c
March 1, 2016 7:02 AM EST
BTIG initiated coverage on bluebird bio (NASDAQ: BLUE) with a Buy rating and a price target of $72.00.
Analyst Dane Leone said, "BLUE has underperformed the Nasdaq Biotech Index over the past 12 months as disappointing clinical development updates compounded valuation compression within the sector.... More
February 29, 2016 7:07 AM EST
Leerink Partners analyst, Jonathan Chang sees bluebird bio (NASDAQ: BLUE) gene therapy LentiGlobin as the key value driver for the stock with initial clinical proof-of-concept (POC) achieved in hemoglobinopathies and next clinical updates expected at the ASH annual meeting in Dec. Near term, positive Lenti-D interim Ph II/III data in ultra-rare Childhood Cerebral Adrenoleukodystrophy (CCALD) at the American Academy of Neurology (AAN) annual meeting (April 15-21) could represent important platform validation.
CCALD is a rare severe and progressive central nervous system (CNS) disease. While... More
